SCHEMBL4623645

SCHEMBL4623645

CC(=O)c1ccc(C(=O)Cl)cc1C(C)=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
AKR1C3 P42330 6/20 0.38
AKR1C2 P52895 6/20 0.38
HPGD P15428 4/20 0.37
ALDH1A1 P00352 3/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
TSHR P16473 1/20 0.36
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KMT2A Q03164 1/20 0.35
AKR1B10 O60218 1/20 0.35
AKR1B1 P15121 1/20 0.35
AKR1C4 P17516 1/20 0.35
AKR1C1 Q04828 1/20 0.35
HSD17B1 P14061 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4093150 0.90 CDC25A (0.47) AKR1C3AKR1C2ALDH1A1L3MBTL1AKR1B10
SCHEMBL21985528 0.85 SMN1; SMN2 (0.39) MAPTRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL50489 0.84 AKR1C3 (0.49) MAPTRAB9ASMN1; SMN2NPC1AKR1C3
SCHEMBL29361599 0.84 AKR1C3 (0.49) MAPTRAB9ASMN1; SMN2NPC1AKR1C3
SCHEMBL10046615 0.82 L3MBTL1 (0.48) MAPTSMN1; SMN2AKR1C3AKR1C2HPGD
SCHEMBL7898447 0.80 KDM4E (0.52) MAPTRAB9ASMN1; SMN2AKR1C3AKR1C2
SCHEMBL29440655 0.79 ALDH1A1 (0.40) MAPTSMN1; SMN2HPGDALDH1A1TSHR
SCHEMBL75886 0.79 ALDH1A1 (0.40) MAPTSMN1; SMN2HPGDALDH1A1TSHR
SCHEMBL10802946 0.78 PARP1 (0.45) SMN1; SMN2ALDH1A1MAPK1TSHRKMT2A
SCHEMBL28767016 0.78 ALDH1A1 (0.44) MAPTRAB9ASMN1; SMN2NPC1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102727493-B Applications of TEMPOL derivatives as anti-tumor drugs FOURTH MILITARY MEDICAL UNIV 2014-04-23 CN disclosed
CN-102727493-A Applications of TEMPOL derivatives as anti-tumor drugs FOURTH MILITARY MEDICAL UNIV 2012-10-17 CN disclosed
EP-0886639-B1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES GLYCOMIMETICS INC (US) 2008-05-28 EP disclosed
US-6187754-B1 Sialyl-Lewisa and sialyl-Lewisx epitode analogues GLYCOTECH CORP. 2001-02-13 US disclosed
EP-0886639-A1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES GlycoTech Corp. (US) 1998-12-30 EP disclosed
WO-1997028174-A1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES NOVARTIS AG (CH) 1997-08-07 WO disclosed